drugset / Trial / NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Timeline
- Start
- 2024-03-25
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IAM1363 | Unknown | — | Oral |
| Background | Capecitabine | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | T-Dxd | Unknown | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |
| Background | Zanidatamab | Monoclonal antibody | — | — |